{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:50:30Z","timestamp":1787964630605,"version":"build-2784847793"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["1ZIADC000079-01"],"award-info":[{"award-number":["1ZIADC000079-01"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["1ZICDC000080-03"],"award-info":[{"award-number":["1ZICDC000080-03"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["JARO"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cisplatin is a widely used anti-cancer drug used to treat a variety of cancer types. One of the side effects of this life-saving drug is irreversible ototoxicity, resulting in permanent hearing loss in many patients. In order to understand why cisplatin is particularly toxic to the inner ear, we compared the hearing loss and cochlear uptake of cisplatin to that of two related drugs, carboplatin and oxaliplatin. These three drugs are similar in that each contains a core platinum atom; however, carboplatin and oxaliplatin are considered less ototoxic than cisplatin. We delivered these three drugs to mice using a 6-week cyclic drug administration protocol. We performed the experiment twice, once using equimolar concentrations of the drugs and once using concentrations of the drugs more proportional to those used in the clinic. For both concentrations, we detected a significant hearing loss caused by cisplatin and no hearing loss caused by carboplatin or oxaliplatin. Cochlear uptake of each drug was measured using inductively coupled plasma mass spectrometry (ICP-MS) to detect platinum. Cochlear platinum levels were highest in mice treated with cisplatin followed by oxaliplatin, while carboplatin was largely excluded from the cochlea. Even when the drug doses were increased, cochlear platinum remained low in mice treated with oxaliplatin or carboplatin. We also examined drug clearance from the inner ear by measuring platinum levels at 1\u00a0h and 24\u00a0h after drug administration. Our findings suggest that the reduced cochlear platinum we observed with oxaliplatin and carboplatin were not due to increased clearance of these drugs relative to cisplatin. Taken together, our data indicate that the differential ototoxicity among cisplatin, carboplatin, and oxaliplatin is attributable to differences in cochlear uptake of these three drugs.<\/jats:p>","DOI":"10.1007\/s10162-020-00759-y","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T10:03:20Z","timestamp":1592993000000},"page":"303-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents"],"prefix":"10.1007","volume":"21","author":[{"given":"Benjamin K.","family":"Gersten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy S.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0522-388X","authenticated-orcid":false,"given":"Katharine A.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa L.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"759_CR1","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jager E (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435\u20131442","journal-title":"J Clin Oncol"},{"key":"759_CR2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1021\/js960037a","volume":"85","author":"A Andersson","year":"1996","unstructured":"Andersson A, Fagerberg J, Lewensohn R, Ehrsson H (1996) Pharmacokinetics of cisplatin and its monohydrated complex in humans. J Pharm Sci 85:824\u2013827","journal-title":"J Pharm Sci"},{"issue":"4","key":"759_CR3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/16513860802527930","volume":"6","author":"L Astolfi","year":"2008","unstructured":"Astolfi L, Simoni E, Ciorba A, Martini A (2008) In vitro protective effects of Ginkgo bilboa against cisplatin toxicity in mouse cell line OCk3. Audiol Med 6(4):251\u2013258","journal-title":"Audiol Med"},{"key":"759_CR4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/pbc.24830","volume":"61","author":"JK Bass","year":"2014","unstructured":"Bass JK, Huang J, Onar-Thomas A, Chang KW, Bhagat SP, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath JA, McCowage G, Cohn RJ, Fisher MJ, Robinson G, Broniscer A, Gajjar A, Gurney JG (2014) Concordance between the Chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer 61:601\u2013605","journal-title":"Pediatr Blood Cancer"},{"key":"759_CR5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1040-8428(01)00169-X","volume":"40","author":"Y Becouarn","year":"2001","unstructured":"Becouarn Y, Agostini C, Trufflandier N, Boulanger V (2001) Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol 40:265\u2013272","journal-title":"Crit Rev Oncol Hematol"},{"key":"759_CR6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.mph.0000141348.62532.73","volume":"26","author":"P Bertolini","year":"2004","unstructured":"Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O (2004) Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649\u2013655","journal-title":"J Pediatr Hematol Oncol"},{"key":"759_CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000093776","volume":"70","author":"K Biro","year":"2006","unstructured":"Biro K, Noszek L, Prekopp P, Nagyivanyi K, Geczi L, Gaudi I, Bodrogi I (2006) Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology 70:177\u2013184","journal-title":"Oncology"},{"key":"759_CR8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/019459989310900302","volume":"109","author":"BW Blakley","year":"1993","unstructured":"Blakley BW, Myers SF (1993) Patterns of hearing loss resulting from cis-platinum therapy. Otolaryngol Head Neck Surg 109:385\u2013391","journal-title":"Otolaryngol Head Neck Surg"},{"key":"759_CR9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1044\/1092-4388(2001\/022)","volume":"44","author":"PJ Blamey","year":"2001","unstructured":"Blamey PJ, Sarant JZ, Paatsch LE, Barry JG, Bow CP, Wales RJ, Wright M, Psarros C, Rattigan K, Tooher R (2001) Relationships among speech perception, production, language, hearing loss, and age in children with impaired hearing. J Speech Lang Hear Res 44:264\u2013285","journal-title":"J Speech Lang Hear Res"},{"issue":"Suppl 4","key":"759_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1998.427","volume":"77","author":"H Bleiberg","year":"1998","unstructured":"Bleiberg H (1998) Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 77(Suppl 4):1\u20133","journal-title":"Br J Cancer"},{"key":"759_CR11","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/bjc.1998.226","volume":"77","author":"C Bokemeyer","year":"1998","unstructured":"Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77:1355\u20131362","journal-title":"Br J Cancer"},{"key":"759_CR12","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/s41467-017-01837-1","volume":"8","author":"AM Breglio","year":"2017","unstructured":"Breglio AM, Rusheen AE, Shide ED, Fernandez KA, Spielbauer KK, McLachlin KM, Hall MD, Amable L, Cunningham LL (2017) Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun 8:1654","journal-title":"Nat Commun"},{"key":"759_CR13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/mas.20159","volume":"27","author":"EE Brouwers","year":"2008","unstructured":"Brouwers EE, Tibben M, Rosing H, Schellens JH, Beijnen JH (2008) The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research. Mass Spectrom Rev 27:67\u2013100","journal-title":"Mass Spectrom Rev"},{"key":"759_CR14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF00257742","volume":"9","author":"AH Calvert","year":"1982","unstructured":"Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140\u2013147","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"759_CR15","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/00129492-200411000-00009","volume":"25","author":"W-T Choe","year":"2004","unstructured":"Choe W-T, Chinosornvatana N, Chang KW (2004) Prevention of cisplatin ototoxicity using transtympanic N-Acetylcysteine and lactate. Otol and Neurotol 25(6):910\u2013915","journal-title":"Otol and Neurotol"},{"key":"759_CR16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/17425255.2011.547474","volume":"7","author":"G Ciarimboli","year":"2011","unstructured":"Ciarimboli G (2011) Role of organic cation transporters in drug-induced toxicity. Expert Opin Drug Metab Toxicol 7:159\u2013174","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"759_CR17","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2353\/ajpath.2010.090610","volume":"176","author":"G Ciarimboli","year":"2010","unstructured":"Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstadt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, Jurgens H, Schlatter E (2010) Organic cation transporter 2 mediates cisplatin-induced Oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176:1169\u20131180","journal-title":"Am J Pathol"},{"key":"759_CR18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2016.09.023","volume":"69","author":"E Clemens","year":"2016","unstructured":"Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, van der Pal HJ, van Grotel M, van den Heuvel-Eibrink MM (2016) Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: a DCOG late-effects study. Eur J Cancer 69:77\u201385","journal-title":"Eur J Cancer"},{"key":"759_CR19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/01.aud.0000240640.59205.42","volume":"27","author":"CM Connor","year":"2006","unstructured":"Connor CM, Craig HK, Raudenbush SW, Heavner K, Zwolan TA (2006) The age at which young deaf children receive cochlear implants and their vocabulary and speech-production growth: is there an added value for early implantation? Ear Hear 27:628\u2013644","journal-title":"Ear Hear"},{"key":"759_CR20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.20516","volume":"81","author":"BR Curtis","year":"2006","unstructured":"Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, McFarland JG, Aster RH (2006) Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 81:193\u2013198","journal-title":"Am J Hematol"},{"key":"759_CR21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1672-2930(13)50009-2","volume":"8","author":"D Dalian","year":"2013","unstructured":"Dalian D, Haiyan J, Yong F, Yongqi L, Salvi R, Someya S, Tanokura M (2013) Ototoxic model of oxaliplatin and protection from nicotinamide adenine dinucleotide. J Otol 8:63\u201371","journal-title":"J Otol"},{"key":"759_CR22","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3109\/00016489.2013.879740","volume":"134","author":"P Dammeyer","year":"2014","unstructured":"Dammeyer P, Hellberg V, Wallin I, Laurell G, Shoshan M, Ehrsson H, Arner ES, Kirkegaard M (2014) Cisplatin and oxaliplatin are toxic to cochlear outer hair cells and both target thioredoxin reductase in organ of Corti cultures. Acta Otolaryngol 134:448\u2013454","journal-title":"Acta Otolaryngol"},{"key":"759_CR23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/010503999424707","volume":"28","author":"A De Lauretis","year":"1999","unstructured":"De Lauretis A, De Capua B, Barbieri MT, Bellussi L, Passali D (1999) ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin. Scand Audiol 28:139\u2013143","journal-title":"Scand Audiol"},{"key":"759_CR24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MPH.0b013e31815d1d83","volume":"30","author":"JB Dean","year":"2008","unstructured":"Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ (2008) Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol 30:130\u2013134","journal-title":"J Pediatr Hematol Oncol"},{"key":"759_CR25","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320\u20131329","journal-title":"J Natl Cancer Inst"},{"key":"759_CR26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jat\/32.2.140","volume":"32","author":"D Esteban-Fernandez","year":"2008","unstructured":"Esteban-Fernandez D, Verdaguer JM, Ramirez-Camacho R, Palacios MA, Gomez-Gomez MM (2008) Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration. J Anal Toxicol 32:140\u2013146","journal-title":"J Anal Toxicol"},{"key":"759_CR27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.heares.2019.02.006","volume":"375","author":"K Fernandez","year":"2019","unstructured":"Fernandez K, Wafa T, Fitzgerald TS, Cunningham LL (2019) An optimized, clinically relevant mouse model of cisplatin-induced ototoxicity. Hear Res 375:66\u201374","journal-title":"Hear Res"},{"key":"759_CR28","doi-asserted-by":"crossref","unstructured":"Fernandez K, Spielbauer KK, Rusheen A, Wang L, Baker TG, Eyles S, Cunningham LL (2020) Lovastatin protects against cisplatin-induced hearing loss in mice. Hear Res 389:107905","DOI":"10.1016\/j.heares.2020.107905"},{"key":"759_CR29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000442435","volume":"21","author":"AR Fetoni","year":"2016","unstructured":"Fetoni AR, Ruggiero A, Lucidi D, De Corso E, Sergi B, Conti G, Paludetti G (2016) Audiological monitoring in children treated with platinum chemotherapy. Audiol Neurootol 21:203\u2013211","journal-title":"Audiol Neurootol"},{"key":"759_CR30","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2016.66.8822","volume":"34","author":"RD Frisina","year":"2016","unstructured":"Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, Lipshultz SE, Dolan ME, Travis LB (2016) Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 34:2712\u20132720","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"759_CR31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1525-1438.2007.01101.x","volume":"18","author":"K Fujiwara","year":"2008","unstructured":"Fujiwara K (2008) Can carboplatin replace cisplatin for intraperitoneal use? Int J Gynecol Cancer 18(Suppl 1):29\u201332","journal-title":"Int J Gynecol Cancer"},{"key":"759_CR32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/sonc.2002.35525","volume":"29","author":"E Gamelin","year":"2002","unstructured":"Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29:21\u201333","journal-title":"Semin Oncol"},{"key":"759_CR33","doi-asserted-by":"crossref","first-page":"e1229","DOI":"10.1542\/peds.2007-0178","volume":"120","author":"JG Gurney","year":"2007","unstructured":"Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML (2007) Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children\u2019s Oncology Group. Pediatrics 120:e1229\u2013e1236","journal-title":"Pediatrics"},{"key":"759_CR34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1179\/1973947815Y.0000000023","volume":"28","author":"MG Guvenc","year":"2016","unstructured":"Guvenc MG, Dizdar D, Dizdar SK, Okutur SK, Demir G (2016) Sudden hearing loss due to oxaliplatin use in a patient with colon cancer. J Chemother 28:341\u2013342","journal-title":"J Chemother"},{"key":"759_CR35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jnci\/djn418","volume":"101","author":"V Hellberg","year":"2009","unstructured":"Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M, Eksborg S, Arner ES, Shoshan M, Ehrsson H, Laurell G (2009) Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 101:37\u201347","journal-title":"J Natl Cancer Inst"},{"key":"759_CR36","doi-asserted-by":"crossref","unstructured":"Honda S, Tsujimoto M, Minegaki T, Mori T, Muraoka J, Nishiguchi K (2019) A case of idiosyncratic liver injury after oxaliplatin-induced thrombocytopenia. J Clin Pharm Ther","DOI":"10.1111\/jcpt.13068"},{"issue":"Suppl 7","key":"759_CR37","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1002\/jcph.706","volume":"56","author":"A Hucke","year":"2016","unstructured":"Hucke A, Ciarimboli G (2016) The role of transporters in the toxicity of chemotherapeutic drugs: focus on transporters for organic cations. J Clin Pharmacol 56(Suppl 7):S157\u2013S172","journal-title":"J Clin Pharmacol"},{"key":"759_CR38","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1007\/s00204-019-02557-9","volume":"93","author":"A Hucke","year":"2019","unstructured":"Hucke A, Rinschen MM, Bauer OB, Sperling M, Karst U, K\u00f6ppen C, Sommer K, Schr\u00f6ter R, Ceresa C, Chiorazzi A, Canta A, Semperboni S, Marmiroli P, Cavaletti G, Schlatt S, Schlatter E, Pavenst\u00e4dt H, Heitplatz B, van Marck V, Sparreboom A, Barz V, Knief A, Deuster D, Zehnhoff-Dinnesen A, Ciarimboli G (2019) An integrative approach to cisplatin chronic toxicities in mice reveals importance of organic cation-transporter-dependent protein networks for renoprotection. Arch Toxicol 93:2835\u20132848","journal-title":"Arch Toxicol"},{"key":"759_CR39","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1093\/annonc\/mds074","volume":"23","author":"DL Jardim","year":"2012","unstructured":"Jardim DL, Rodrigues CA, Novis YAS, Rocha VG, Hoff PM (2012) Oxaliplatin-related thrombocytopenia. Ann Oncol 23:1937\u20131942","journal-title":"Ann Oncol"},{"key":"759_CR40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/BF02897206","volume":"26","author":"IC Kennedy","year":"1990","unstructured":"Kennedy IC, Fitzharris BM, Colls BM, Atkinson CH (1990) Carboplatin is ototoxic. Cancer Chemother Pharmacol 26:232\u2013234","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"759_CR41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbrc.2014.04.118","volume":"27","author":"J Kim","year":"2014","unstructured":"Kim J, Cho H-J, Sagong B, Kim S-J, Lee J-T, So H-S, Lee I-K, Kim U-K, Lee K-Y, Cho Y-S (2014) Alpha-lipoic acid protects against cisplatin-induced ototoxicity via the regulation of MAPKs and proinflammatory cytokines. Biochem Biophys Res Comm 27(2):183\u2013189","journal-title":"Biochem Biophys Res Comm"},{"key":"759_CR42","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1080\/14992027.2017.1398421","volume":"57","author":"D Konrad-Martin","year":"2018","unstructured":"Konrad-Martin D, Poling GL, Garinis AC, Ortiz CE, Hopper J, O'Connell Bennett K, Dille MF (2018) Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions. Int J Audiol 57:S3\u2013s18","journal-title":"Int J Audiol"},{"key":"759_CR43","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.tips.2013.05.006","volume":"34","author":"T Langer","year":"2013","unstructured":"Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O (2013) Understanding platinum-induced ototoxicity. Trends Pharmacol Sci 34:458\u2013469","journal-title":"Trends Pharmacol Sci"},{"key":"759_CR44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2217\/pgs.14.182","volume":"16","author":"C Lanvers-Kaminsky","year":"2015","unstructured":"Lanvers-Kaminsky C, Sprowl JA, Malath I, Deuster D, Eveslage M, Schlatter E, Mathijssen RH, Boos J, Jurgens H, Am Zehnhoff-Dinnesen AG, Sparreboom A, Ciarimboli G (2015) Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics 16:323\u2013332","journal-title":"Pharmacogenomics"},{"key":"759_CR45","first-page":"158","volume":"20","author":"G Laurell","year":"1991","unstructured":"Laurell G, Bagger-Sjoback D (1991) Dose-dependent inner ear changes after i.v. administration of cisplatin. J Otolaryngol 20:158\u2013167","journal-title":"J Otolaryngol"},{"key":"759_CR46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0378-5955(89)90124-X","volume":"38","author":"G Laurell","year":"1989","unstructured":"Laurell G, Engstrom B (1989) The combined effect of cisplatin and furosemide on hearing function in guinea pigs. Hear Res 38:19\u201326","journal-title":"Hear Res"},{"key":"759_CR47","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1080\/000164800750061624","volume":"120","author":"G Laurell","year":"2000","unstructured":"Laurell G, Viberg A, Teixeira M, Sterkers O, Ferrary E (2000) Blood-perilymph barrier and ototoxicity: an in vivo study in the rat. Acta Otolaryngol 120:796\u2013803","journal-title":"Acta Otolaryngol"},{"key":"759_CR48","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000099020","volume":"12","author":"G Laurell","year":"2007","unstructured":"Laurell G, Ekborn A, Viberg A, Canlon B (2007) Effects of a single high dose of cisplatin on the melanocytes of the stria vascularis in the guinea pig. Audiol Neurootol 12:170\u2013178","journal-title":"Audiol Neurootol"},{"key":"759_CR49","first-page":"588","volume":"14","author":"Z Li","year":"2011","unstructured":"Li Z, Hou M, Wang H, Wang Z (2011a) A randomized study of gemcitabine plus oxaliplatin versus gemcitabine plus cisplatin as the 1st line chemotherapy for advanced non-small cell lung cancer in elderly patients. Zhongguo Fei Ai Za Zhi 14:588\u2013592","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"759_CR50","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3748\/wjg.v17.i8.1082","volume":"17","author":"XD Li","year":"2011","unstructured":"Li XD, Shen H, Jiang JT, Zhang HZ, Zheng X, Shu YQ, Wu CP (2011b) Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer. World J Gastroenterol 17:1082\u20131087","journal-title":"World J Gastroenterol"},{"key":"759_CR51","doi-asserted-by":"crossref","first-page":"e1348","DOI":"10.1542\/peds.2009-2448","volume":"125","author":"JE Lieu","year":"2010","unstructured":"Lieu JE, Tye-Murray N, Karzon RK, Piccirillo JF (2010) Unilateral hearing loss is associated with worse speech-language scores in children. Pediatrics 125:e1348\u2013e1355","journal-title":"Pediatrics"},{"issue":"12","key":"759_CR52","volume":"11","author":"H Liu","year":"2016","unstructured":"Liu H, Li Y, Chen L, Zhang Q, Pan N, Nichols DH, Zhang WJ, Fritzsch B, He DZZ (2016) Organ of Corti and stria vascularis: is there an interdependence for survival? PLoS One 11(12):e0168953","journal-title":"PLoS One"},{"key":"759_CR53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-079X.2001.280202.x","volume":"28","author":"MA Lopez-Gonzalez","year":"2000","unstructured":"Lopez-Gonzalez MA, Guerrero JM, Rojas F, Delgado F (2000) Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res 28:73\u201380","journal-title":"J Pineal Res"},{"key":"759_CR54","first-page":"151","volume":"23","author":"MR Macdonald","year":"1994","unstructured":"Macdonald MR, Harrison RV, Wake M, Bliss B, Macdonald RE (1994) Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol 23:151\u2013159","journal-title":"J Otolaryngol"},{"key":"759_CR55","unstructured":"Massachusetts Eye and Ear (2020a) Mouse cochlear dissection. https:\/\/vimeocom\/144531710 Viewed 16 April 2020"},{"key":"759_CR56","unstructured":"Massachusetts Eye and Ear (2020b) ImageJ plug in: mapping cochlear length to cochlear frequency. https:\/\/www.masseyeandear.org\/research\/otolaryngology\/eaton-peabody-laboratories\/histology-core. Viewed 16 April 2020"},{"key":"759_CR57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3892\/ol.2012.997","volume":"5","author":"A Nitz","year":"2013","unstructured":"Nitz A, Kontopantelis E, Bielack S, Koscielniak E, Klingebiel T, Langer T, Paulides M (2013) Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. Oncol Lett 5:311\u2013315","journal-title":"Oncol Lett"},{"issue":"Suppl 4","key":"759_CR58","first-page":"19","volume":"59","author":"PJ O'Dwyer","year":"2000","unstructured":"O'Dwyer PJ, Stevenson JP, Johnson SW (2000) Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59(Suppl 4):19\u201327","journal-title":"Drugs"},{"key":"759_CR59","first-page":"676","volume":"14","author":"SY Oh","year":"2013","unstructured":"Oh SY, Wasif N, Garcon MC, Rodriguez G, Saif MW (2013) Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. JOP 14:676\u2013679","journal-title":"JOP"},{"key":"759_CR60","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194\u20133200","journal-title":"J Clin Oncol"},{"key":"759_CR61","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/sj.bmt.1701391","volume":"22","author":"SK Parsons","year":"1998","unstructured":"Parsons SK, Neault MW, Lehmann LE, Brennan LL, Eickhoff CE, Kretschmar CS, Diller LR (1998) Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 22:669\u2013674","journal-title":"Bone Marrow Transplant"},{"key":"759_CR62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.01.001","volume":"59","author":"LM Pasetto","year":"2006","unstructured":"Pasetto LM, D'Andrea MR, Rossi E, Monfardini S (2006) Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 59:159\u2013168","journal-title":"Crit Rev Oncol Hematol"},{"key":"759_CR63","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/pbc.25123","volume":"61","author":"E Peleva","year":"2014","unstructured":"Peleva E, Emami N, Alzahrani M, Bezdjian A, Gurberg J, Carret AS, Daniel SJ (2014) Incidence of platinum-induced ototoxicity in pediatric patients in Quebec. Pediatr Blood Cancer 61:2012\u20132017","journal-title":"Pediatr Blood Cancer"},{"key":"759_CR64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000094376","volume":"56","author":"A Pietrangeli","year":"2006","unstructured":"Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C (2006) Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56:13\u201316","journal-title":"Eur Neurol"},{"key":"759_CR65","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2011.36.9744","volume":"30","author":"I Qaddoumi","year":"2012","unstructured":"Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, Merchant TE, Haik BG, Wilson MW, Rodriguez-Galindo C (2012) Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30:1034\u20131041","journal-title":"J Clin Oncol"},{"key":"759_CR66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9\u201323","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"759_CR67","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1200\/JCO.2006.10.077","volume":"24","author":"JM Rademaker-Lakhai","year":"2006","unstructured":"Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJW, van Zandwijk N, Schellens JHM (2006) Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 24(6):918\u2013924","journal-title":"J Clin Oncol"},{"issue":"4","key":"759_CR68","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.etp.2016.01.003","volume":"68","author":"A Rold\u00e1n-Fidalgo","year":"2016","unstructured":"Rold\u00e1n-Fidalgo A, Mart\u00edn Salda\u00f1a S, Trinidad A, Olmedilla-Alonso B, Rodr\u00edguez-Valiente A, Garc\u00eda-Berrocal JR, Ram\u00edrez-Camacho R (2016) In vitro and in vivo effects of lutein against cisplatin-induced ototoxicity. Exp Toxicol Pathol 68(4):197\u2013204","journal-title":"Exp Toxicol Pathol"},{"key":"759_CR69","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","volume":"30","author":"A Rossi","year":"2012","unstructured":"Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Fruh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee SM (2012) Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 30:1692\u20131698","journal-title":"J Clin Oncol"},{"key":"759_CR70","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1172\/JCI71353","volume":"123","author":"S Roy","year":"2013","unstructured":"Roy S, Ryals MM, Van den Bruele AB, Fitzgerald TS, Cunningham LL (2013) Sound preconditioning therapy inhibits ototoxic hearing loss in mice. J Clin Invest 123:4945\u20134949","journal-title":"J Clin Invest"},{"issue":"2","key":"759_CR71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/toxsci\/47.2.195","volume":"47","author":"LP Rybak","year":"1999","unstructured":"Rybak LP, Husain K, Whitworh SSM (1999) Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats antioxidant defense system. Toxicol Sci 47(2):195\u2013202","journal-title":"Toxicol Sci"},{"key":"759_CR72","unstructured":"Saif MW, Reardon J (2005) Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 1:249\u2013258"},{"key":"759_CR73","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/ar.22578","volume":"295","author":"J Schacht","year":"2012","unstructured":"Schacht J, Talaska AE, Rybak LP (2012) Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec (Hoboken) 295:1837\u20131850","journal-title":"Anat Rec (Hoboken)"},{"key":"759_CR74","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/1097-0142(19851015)56:8<1934::AID-CNCR2820560807>3.0.CO;2-F","volume":"56","author":"SD Schaefer","year":"1985","unstructured":"Schaefer SD, Post JD, Close LG, Wright CG (1985) Ototoxicity of low- and moderate-dose cisplatin. Cancer 56:1934\u20131939","journal-title":"Cancer"},{"key":"759_CR75","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.1989.7.6.754","volume":"7","author":"MJ Schell","year":"1989","unstructured":"Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, Meyer WH (1989) Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 7:754\u2013760","journal-title":"J Clin Oncol"},{"key":"759_CR76","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/019459988409200109","volume":"92","author":"VG Schweitzer","year":"1984","unstructured":"Schweitzer VG, Hawkins JE, Lilly DJ, Litterst CJ, Abrams G, Davis JA, Christy M (1984) Ototoxic and nephrotoxic effects of combined treatment with cis-diamminedichloroplatinum and kanamycin in the guinea pig. Otolaryngol Head Neck Surg 92:38\u201349","journal-title":"Otolaryngol Head Neck Surg"},{"key":"759_CR77","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/019459988609400410","volume":"94","author":"VG Schweitzer","year":"1986","unstructured":"Schweitzer VG, Rarey KE, Dolan DF, Abrams G, Litterst CJ, Sheridan C (1986) Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9). Otolaryngol Head Neck Surg 94:458\u2013470","journal-title":"Otolaryngol Head Neck Surg"},{"key":"759_CR78","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fncel.2017.00338","volume":"11","author":"S Sheth","year":"2017","unstructured":"Sheth S, Mukherjea D, Rybak LP, Ramkumar V (2017) Mechanisms of cisplatin-induced ototoxicity and otoprotection. Front Cell Neurosci 11:338","journal-title":"Front Cell Neurosci"},{"key":"759_CR79","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/oxfordjournals.annonc.a058931","volume":"5","author":"DV Skarlos","year":"1994","unstructured":"Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, Mylonakis N, Provata A, Papadakis E, Klouvas G, Theocharis D, Panousaki E, Boleti E, Sphakianoudis G, Pavlidis N (1994) Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 5:601\u2013607","journal-title":"Ann Oncol"},{"key":"759_CR80","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/0284186X.2016.1197420","volume":"55","author":"M Stefansson","year":"2016","unstructured":"Stefansson M, Nygren P (2016) Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life. Acta Oncol 55:1227\u20131235","journal-title":"Acta Oncol"},{"key":"759_CR81","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5045\/br.2014.49.1.61","volume":"49","author":"SE Suh","year":"2014","unstructured":"Suh SE, Jang MJ, Chong SY, Aster RH, Curtis BR, Oh D (2014) A case of oxaliplatin-induced immune-mediated thrombocytopenia. Blood Res 49:61\u201364","journal-title":"Blood Res"},{"key":"759_CR82","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","volume":"37","author":"KS Tewari","year":"2019","unstructured":"Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ (2019) Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol 37:2317\u20132328","journal-title":"J Clin Oncol"},{"key":"759_CR83","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/0959-8049(92)90519-8","volume":"28a","author":"P Tothill","year":"1992","unstructured":"Tothill P, Klys HS, Matheson LM, McKay K, Smyth JF (1992) The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer 28a:1358\u20131361","journal-title":"Eur J Cancer"},{"key":"759_CR84","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1007\/s10147-014-0667-5","volume":"19","author":"M Uchida","year":"2014","unstructured":"Uchida M, Kawai K, Kimura T, Ichioka D, Takaoka E, Suetomi T, Miyazaki J, Nishiyama H (2014) Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer. Int J Clin Oncol 19:1112\u20131117","journal-title":"Int J Clin Oncol"},{"key":"759_CR85","first-page":"319","volume":"49","author":"MH Ullman-Cullere","year":"1999","unstructured":"Ullman-Cullere MH, Foltz CJ (1999) Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci 49:319\u2013323","journal-title":"Lab Anim Sci"},{"key":"759_CR86","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00464252","volume":"239","author":"LG van Zeijl","year":"1984","unstructured":"van Zeijl LG, Conijn EA, Rodenburg M, Tange RA, Brocaar MP (1984) Analysis of hearing loss due to cis-diamminedichloroplatinum-II. Arch Otorhinolaryngol 239:255\u2013262","journal-title":"Arch Otorhinolaryngol"},{"key":"759_CR87","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2165\/00003495-198937020-00005","volume":"37","author":"AJ Wagstaff","year":"1989","unstructured":"Wagstaff AJ, Ward A, Benfield P, Heel RC (1989) Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37:162\u2013190","journal-title":"Drugs"},{"key":"759_CR88","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijporl.2018.06.021","volume":"111","author":"S Waissbluth","year":"2018","unstructured":"Waissbluth S, Del Valle A, Chuang A, Becker A (2018a) Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients. Int J Pediatr Otorhinolaryngol 111:174\u2013179","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"759_CR89","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijporl.2018.01.028","volume":"107","author":"S Waissbluth","year":"2018","unstructured":"Waissbluth S, Chuang A, Del Valle A, Cordova M (2018b) Long term platinum-induced ototoxicity in pediatric patients. Int J Pediatr Otorhinolaryngol 107:75\u201379","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"759_CR90","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/JTO.0b013e3181ffe8ef","volume":"6","author":"CH Weissman","year":"2011","unstructured":"Weissman CH, Reynolds CH, Neubauer MA, Pritchard S, Kobina S, Asmar L (2011) A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 6:358\u2013364","journal-title":"J Thorac Oncol"},{"key":"759_CR91","doi-asserted-by":"crossref","unstructured":"Woo HS, Lee KH, Yoon PH, Kim SJ, Park I, Kim YS, Ahn HK, Hong J, Shin DB, Sym JS, (2015) Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report. Cancer Res Treat 47(4):949\u2013953","DOI":"10.4143\/crt.2014.052"},{"key":"759_CR92","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/pbc.24138","volume":"59","author":"A Yancey","year":"2012","unstructured":"Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J (2012) Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer 59:144\u2013148","journal-title":"Pediatr Blood Cancer"},{"key":"759_CR93","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/jpet.106.110346","volume":"319","author":"A Yonezawa","year":"2006","unstructured":"Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K (2006) Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319:879\u2013886","journal-title":"J Pharmacol Exp Ther"},{"key":"759_CR94","doi-asserted-by":"crossref","first-page":"e1072","DOI":"10.1097\/MD.0000000000001072","volume":"94","author":"J Yu","year":"2015","unstructured":"Yu J, Xiao J, Yang Y, Cao B (2015) Oxaliplatin-based doublets versus cisplatin or carboplatin-based doublets in the first-line treatment of advanced nonsmall cell lung cancer. Medicine (Baltimore) 94:e1072","journal-title":"Medicine (Baltimore)"},{"key":"759_CR95","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3906\/sag-1304-76","volume":"44","author":"S Yuce","year":"2014","unstructured":"Yuce S, Seker MM, Koc S, Uysal IO, Kacan T, Dogan M, Dogan M, Babacan NA, Kilickap S (2014) Oxaliplatin and ototoxicity: is it really safe for hearing? Turk J Med Sci 44:586\u2013589","journal-title":"Turk J Med Sci"},{"key":"759_CR96","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.7150\/jca.28896","volume":"10","author":"F Zhang","year":"2019","unstructured":"Zhang F, Zhang Y, Jia Z, Wu H, Gu K (2019) Oxaliplatin-based regimen is superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer: a meta-analysis. J Cancer 10:1923\u20131929","journal-title":"J Cancer"},{"key":"759_CR97","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000095818","volume":"11","author":"CL Zuur","year":"2006","unstructured":"Zuur CL, Simis YJ, Lansdaal PE, Rasch CR, Tange RA, Balm AJ, Dreschler WA (2006) Audiometric patterns in ototoxicity of intra-arterial cisplatin chemoradiation in patients with locally advanced head and neck cancer. Audiol Neurootol 11:318\u2013330","journal-title":"Audiol Neurootol"}],"container-title":["Journal of the Association for Research in Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10162-020-00759-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10162-020-00759-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10162-020-00759-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T19:06:28Z","timestamp":1624475188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10162-020-00759-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1007\/s10162-020-00759-y","relation":{},"ISSN":["1525-3961","1438-7573"],"issn-type":[{"value":"1525-3961","type":"print"},{"value":"1438-7573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"16 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}